Jim Cramer Doesn't Like This Health Care Stock, Sees No Reason To Buy Rambus

Impact · against what's priced in

The news is largely noise for ADM and DE, as Cramer's bullishness aligns with existing market pricing and cycle expectations. The primary actionable item is a new coverage initiation for MMED with a target suggesting 16% upside, while RMBS faces a potential multiple drag due to a perceived lack of catalysts.

DE+0.00

Already priced in

The price assumes

Fiscal 2026 marking the bottom of the agricultural cycle